Abstract
Arsenite is widely distributed environmental toxicant in water, food and air. It is a known human carcinogen, which is strongly associated with human cancers originated from liver, nasal cavity, lung, skin, bladder, kidney, and prostate. In this study, we investigated whether arsenite induces expression of hypoxia-inducible factor 1 (HIF-1). HIFhyphen;1 is a heterodimeric basic helix-loop-helix transcription factor, composed of HIF-1α and HIF-1β/ARNT subunits; and is involved in tumor growth and angiogenesis. Here we demonstrate that arsenite induces the expression of HIF-1α but not HIF-1β subunit in DU145 human prostate carcinoma cells. Arsenite also increases the expression of VEGF through the induction of HIF-1. We also found that arsenite activates PI3K and Akt that are required for arsenite-induced expression of HIF-1α and VEGF. The induction of HIF-1 and VEGF by arsenite can not be inhibited by MAP kinase inhibitors. Arsenite causes production of reactive oxygen species (ROS). The major species of ROS required for the induction of HIF-1 and VEGF is H2O2. These data indicate that the arsenite-induced activation of PI3K/Akt signaling and the expression of HIF-1 and VEGF through the generation of ROS could be an important mechanism in the arsenite-induced carcinogenesis.
Similar content being viewed by others
References
Kitchin KT: Recent advances in arsenic carcinogenesis: Modes of action, animal model systems, and methylated arsenic metabolites. Toxicol Appl Pharmacol 172: 249–261, 2001
Faroon OM, Williams M, O'Connor R: A review of the carcinogenicity of chemicals most frequently found at National Priorities List sites. Toxicol Ind Health 10: 203–230, 1994
Rojas E, Herrera LA, Poirier LA, Ostrosky-Wegman P: Are metal dietary carcinogens? Mutat Res 443: 157–181, 1999
Chen CJ, Wang CJ: Ecological correlation between arsenic level in well water and age-adjusted mortality from malignant neoplasms. Cancer Res 50: 5470–5474, 1990
Chiou H-Y, Hsueh YM, Liaw KF, Horng SF, Chiang MH, Pu YS, Lin JS, Huang CH, Chen CJ: Incidence of internal cancers and ingested inorganic arsenic: A seven year follow up study in Taiwan. Cancer Res 55: 1296–1330, 1995
Chen CJ, Chen CW, Wu M-M, Kuo T-L: Cancer potential in liver, lung, bladder and kidney due to ingested inorganic in drinking water. Br J Cancer 66: 888–892, 1992
Li JH, Rossman TG: Comutagenesis of sodium arsenite with ultraviolet radiation in Chinese hamster V79 cells. Biol Metals 4: 197–200, 1991
Lee-Chen SF, Yu CT, Jan KY: Effect of arsenite on the DNA repair of UV-irradiated Chinese hamster ovary cells. Mutagenesis 7: 51–55, 1992
Salazar AM, Ostrosky-Wegman P, Menendez D, Miranda E, Garcia-Carranca A, Rojas E: Induction of p53 protein expression by sodium arsenite. Mutat Res 381: 259–265, 1997
Chen F, Zhang Z, Bower J. Lu Y, Leonard SS, Ding M, Castranova V, Piwnica-Worms H, Shi X: Arsenite-induced Cdc25C degradation is through the KEN-box and ubiquitin-proteasome pathway. Proc Natl Acad Sci USA 99: 1990–1995, 2002
Miller WH Jr, Schipper HM, Lee JS, Singer J, Waxman S: Mechanisms of activation of arsenic trioxide. Cancer Res 62: 3893–3903, 2002
Kim JY, Choi JA, Kim TH, Yoo YD, Kim JI, Lee YJ, Yoo SY, Cho CK, Lee YS, Lee SJ: Involvement of p38 mitogen-activated protein kinase in the cell growth inhibition by sodium arsenite. J Cell Physiol 190: 29–37, 2002
Chen F, Lu Y, Zhang Z, Vallyathan Y, Ding M, Castranova V, Shi X: Opposite effect of NF-κB and c-Jun N-terminal kinase on p53-independent GADD45 induction by arsenite. J Biol Chem 276: 11414–11419, 2001
Cavigelli M, Li WW, Lin A, Su B, Yoshioka K, Karin M: The tumor promoter arsenite stimulates AP-1 activity by inhibiting a JNK phosphatase. EMBO J 15: 6269–6279, 1996
Hayes RB: The carcinogenicity of metals in humans. Cancer Causes Control 8: 371–385, 1997
Jiang BH, Rue E, Wang GL, Roe R, Semenza GL: Dimerization, DNA binding, and transactivation properties of hypoxia-inducible factor 1. J Biol Chem 271: 17771–17778, 1996
Wang GL, Jiang BH, Rue EA, Semenza GL: Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc Natl Acad Sci USA 92: 5510–5514, 1995
Jiang BH, Semenza GL, Bauer C, Marti HH: Hypoxia-inducible factor 1 levels vary exponentially over a physiologically relevant range of O2 tension. Am J Physiol 271: C1172–C1180, 1996
Hoffman EC, Reyes H, Chu FF, Sander F, Conley LH, Brooks BA, Hankinson O: Cloning of a factor required for activity of the Ah (dioxin) receptor. Science 252: 954–958, 1991
Forsythe JA, Jiang BH, Iyer NV, Agani F, Leung SW, Koos RD, Semenza GL: Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol Cell Biol 16: 4604–4613, 1996
Lee PJ, Jiang BH, Chin BY, Lyer NV, Alam J, Semenza GL, Choi AM: Hypoxia-inducible factor-1 mediates transcriptional activation of the heme oxygenase-1 gene in response to hypoxia. J Biol Chem 272: 5375–5381, 1997
Semenza GL, Jiang BH, Leung SW, Passantino R, Concordet JP, Maire P, Giallongo A: Hypoxia response elements in the aldolase A, enolase 1, and lactate dehydrogenase A gene promoters contain essential binding sites for hypoxia-inducible factor 1. J Biol Chem 271: 32529–32537, 1996
Semenza GL, Agani F, Booth G, Forsythe J, Iyer N, Jiang BH, Leung S, Roe R, Wiener C, Yu A: Structural and functional analysis of hypoxia-inducible factor 1. Kidney Int 51: 553–555, 1997
Jiang BH, Agani F, Passaniti A, Semenza GL: V-SRC induces expression of hypoxia-inducible factor 1 (HIF-1) and transcription of genes encoding vascular endothelial growth factor and enolase 1: Involvement of HIF-1 in tumor progression. Cancer Res 57: 5328–5335, 1997
Maxwell PH, Dachs GU, Gleadle JM, Nicholls LG, Harris AL, Stratford IJ, Hankinson O, Pugh CW, Ratcliffe PJ: Hypoxia-inducible factor-1 modulates gene expression in solid tumors and influences both angiogenesis and tumor growth. Proc Natl Acad Sci USA 94: 8104–8109, 1997
Mazure NM, Chen EY, Laderoute KR, Giaccia AJ: Induction of vascular endothelial growth factor by hypoxia is modulated by a phosphatidylinositol 3-kinase/Akt signaling pathway in Ha-ras-transformed cells through a hypoxia inducible factor-1 transcriptional element. Blood 90: 3322–3331, 1997
Zhong H, De Marzo AM, Laughner E, Lim M, Hilton DA, Zagzag D, Buechler P, Isaacs WB, Semenza GL, Simons JW: Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases. Cancer Res 59: 5830–5835, 1999
Jiang BH, Jiang G, Zheng JZ, Lu Z, Hunter T, Vogt PK: Phosphatidylinositol 3-kinase signaling controls levels of hypoxia-inducible factor 1. Cell Growth Diff 12: 363–369, 2001
Minet E, Arnould T, Michel G, Roland I, Mottet D, Raes M, Remacle J, Michiels C: ERK activation upon hypoxia: Involvement in HIF-1 activation. FEBS Lett 468: 53–58, 2000
Richard DE, Berra E, Gothie E, Roux D, Pouyssegur J: p42/p44 mitogen-activated protein kinases phosphorylate hypoxia-inducible factor 1alpha (HIF-1alpha) and enhance the transcriptional activity of HIF-1. J Biol Chem 274: 32631–32637, 1999
Zhong H, Chiles K, Feldser D, Laughner E, Hanrahan C, Georgescu MM, Simons JW, Semenza GL: Modulation of hypoxia-inducible factor 1alpha expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: Implications for tumor angiogenesis and therapeutics. Cancer Res 60: 1541–1545, 2000
Maxwell PH, Wiesener MS, Chang GW, Clifford SC, Vaux EC, Cockman ME, Wykoff CC, Pugh CW, Maher ER, Ratcliffe PJ: The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 399: 271–275, 1999
Cockman ME, Masson N, Mole DR, Jaakkola P, Chang GW, Clifford SC, Maher ER, Pugh CW, Ratcliffe PJ, Maxwell PH: Hypoxia inducible factor-alpha binding and ubiquitylation by the von Hippel-Lindau tumor suppressor protein. J Biol Chem 275: 25733–25741, 2000
Kamura T, Sato S, Iwai K, Czyzyk-Krzeska M, Conaway RC, Conaway JW: Activation of HIF1alpha ubiquitination by a reconstituted von Hippel-Lindau (VHL) tumor suppressor complex. Proc Natl Acad Sci USA 97: 10430–10435, 2000
Ohh M, Park CW, Ivan M, Hoffman MA, Kim TY, Huang LE, Pavletich N, Chau V, Kaelin WG: Ubiquitination of hypoxia-inducible factor requires direct binding to the beta-domain of the von Hippel-Lindau protein. Nat Cell Biol 2: 423–427, 2000
Tanimoto K, Makino Y, Pereira T, Poellinger L: Mechanism of regulation of the hypoxia-inducible factor-1 alpha by the von Hippel-Lindau tumor suppressor protein. EMBO J 19: 4298–4309, 2000
Bruick RK, McKnight SL: A conserved family of prolyl-4-hydroxylases that modify HIF. Science 294: 1337–1340, 2001
Jaakkola P, Mole DR, Tian YM, Wilson MI, Gielbert J, Gaskell SJ, Kriegsheim A, Hebestreit HF, Mukherji M, Schofield CJ, Maxwell PH, Pugh CW, Ratcliffe PJ: Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science 292: 468–472, 2001
Masson N, Willam C, Maxwell PH, Pugh CW, Ratcliffe PJ: Independent function of two destruction domains in hypoxia-inducible factor-alpha chains activated by prolyl hydroxylation. EMBO J 20: 5197–5206, 2001
Liu Y, Cox SR, Morita T, Kourembanas S: Hypoxia regulates vascular endothelial growth factor gene expression in endothelial cells. Identification of a 5′ enhancer. Circ Res 77: 638–643, 1995
Ferrara N, Davis-Smyth T: The biology of vascular endothelial growth factor. Endocr Rev 18: 4–25, 1997
Millauer B, Longhi MP, Plate KH, Shawver LK, Risau W, Ullrich A, Strawn LM: Dominant-negative inhibition of Flk-1 suppresses the growth of many tumor types in vivo. Cancer Res 56: 1615–1620, 1996
Plate KH, Breier G, Weich HA, Risau W: Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo. Nature 359: 845–848, 1992
Plate KH, Breier G, Millauer B, Ullrich A, Risau W: Up-regulation of vascular endothelial growth factor and its cognate receptors in a rat glioma model of tumor angiogenesis. Cancer Res 53: 5822–5827, 1993
Strawn LM, McMahon G, App H, Schreck R, Kuchler WR, Longhi MP, Hui TH, Tang C, Levitzki A, Gazit A, Chen I, Keri G, Orfi L, Risau W, Flamme I, Ullrich A, Hirth KP, Shawver LK: Flk-1 as a target for tumor growth inhibition. Cancer Res 56: 3540–3545, 1996
Liu SX, Athar M, Lippai I, Waldren C, Hei TK: Induction of oxyradicals by arsenic: Implication for mechanism of genotoxicity. Proc Natl Acad Sci USA 98: 1643–1648, 2001
Ding M, Li J-J, Leonard SS, Ye J, Shi X, Colburn NH, Castranova V, Vallyathan V: Vanadate-induced activation of activator protein-1: Role of reactive oxygen species. Carcinogenesis 20: 663–668, 1999
Ye J, Ding M, Leonard SS, Robinson VA, Michecchia L, Zhang X, Castranova V, Vallyathan V, Shi X: Vanadate induces apoptosis in epidermal JB6 P+ cells via hydrogen peroxide-mediated reactions. Mol Cell Biochem 202: 9–17, 1999
Wang S, Leonard SS, Ye J, Ding M, Shi X: The role of hydroxyl radical as a messenger in Cr(VI)-induced p53 activation. Am J Physiol Cell Physiol 279: C868–C875, 2000
Ye J, Wang S, Leonard SS, Sun Y, Butterworth L, Antonini J, Ding M, Rojanasakul Y, Vallyathan V, Castranova V, Shi X: Role of reactive oxygen species and p53 in chromium(VI)-induced apoptosis. J Biol Chem 274: 34974–34980, 1999
Wang S, Shi X: Mechanisms of Cr(VI)-induced p53 activation: The role of phosphorylation, mdm2 and ERK. Carcinogenesis 22: 757–762, 2001
Shi X, Mao Y, Knapton AD, Ding M, Rojanasakul Y, Gannett PM, Dalal NS, Liu K: Reaction of Cr(VI) with ascorbate and hydrogen peroxide generates hydroxyl radicals and causes DNA damage: Role of Cr(IV)-mediated Fenton-like reaction. Carcinogenesis 15: 2475–2478, 1994
Shi X, Dalal NS: Chromium (V) and hydroxyl radical formation during the glutathione reductase-catalyzed reduction of chromium (VI). Biochem Biophys Res Commun 163: 627–634, 1989
Shi X, Dalal NS: On the hydroxyl radical formation in the reaction between hydrogen peroxide and biologically generated chromium (V) species. Arch Biochem Biophys 277: 342–350, 1990
Salceda S, Caro J: Hypoxia-inducible factor 1alpha (HIF-1alpha) protein is rapidly degraded by the ubiquitin-proteasome system under normoxic conditions. Its stabilization by hypoxia depends on redox-induced changes. J Biol Chem 272: 22642–22647, 1997
Sandau KB, Fandrey J, Brune B: Accumulation of HIF-1alpha under the influence of nitric oxide. Blood 97: 1009–1015, 2001
Feldser D, Agani F, Lyer V, Ferrcira G, Semenza GL: Reciprocal positive regulation of hypoxia-inducible factor-1alpha and insulin-like growth factor 2. Cancer Res 59: 3915–3918, 1999
Goldwaser I, Gefel D, Gershonov E, Fridkin M, Shechter Y: Insulin-like effects of vanadium: Basic and clinical implications. J Inorg Biochem 80: 21–25, 2000
Barbagallo M, Dominguez LJ, Resnick LM: Insulin-mimetic action of vanadate: Role of intracellular magnesium. Hypertersion. 38: 701–704, 2001
Minet E, Michel G, Remade J, Michiels C: Role of HIF-1 as a transcription factor involved in embryonic development, cancer progression and apoptosis (review). Int J Mol Med 5: 253–259, 2000
Zelzer E, Levy Y, Kahana C, Shilo BZ, Rubinstein M, Cohen B: Insulin induces transcription of target genes through the hypoxia-inducible factor HIF-1α/ARNT. EMBO J. 17: 5085–5094, 1998
Gong P, Hu B, Steward D, Ellerbe M, Figueroa YG, Blank V, Beckman BS, Alam J: Cobalt induces heme oxygenase-1 expression by a hypoxia-inducible factor-independent mechanism in Chinese hamster ovary cells: Regulation by Nrf2 and MafG transcription factors. J Biol Chem 276: 27018–27025, 2001
Kotch LE, Iyer NV, Laughner E, Semenza GL: Defective vascularization of HIF-1alpha-null embryos is not associated with VEGF deficiency but with mesenchymal cell death. Dev Biol 209: 254–267, 1999
Benjamin LE, Keshet E: Conditional switching of vascular endothelial growth factor (VEGF) expression in tumors: Induction of endothelial cell shedding and regression of hemangioblastoma-like vessels by VEGF withdrawal. Proc Natl Acad Sci USA 94: 8761–8766, 1997
Borgstrom P, Hillan KJ, Sriramarao P, Ferrara N: Complete inhibition of angiogenesis and growth of microtumors by anti-vascular endothelial growth factor neutralizing antibody: Novel concepts of angiostatic therapy from intravital videomicroscopy. Cancer Res 56: 4032–4039, 1996
Cheng S-Y, Huang H-JS, Nagane M, Ji X-D, Wang D, Shih CC-Y, Arap W, Huang C-M, Cavenee WK: Suppression of glioblastoma angiogenicity and tumorigenicity by inhibition of endogenous expression of vascular endothelial growth factor. Proc Natl Acad Sci USA 93: 8502–8507, 1996
Grunstein J, Roberts WG, Mathieu-Costello O, Hanahan D, Johnson RS: Tumor-derived expression of vascular endothelial growth factor is a critical factor in tumor expansion and vascular function. Cancer Res 59: 1592–1598, 1999
Richard DE, Berra E, Pouyssegur J: Nonhypoxic pathway mediates the induction of hypoxia-inducible factor 1alpha in vascular smooth muscle cells. J Biol Chem 275: 26765–26771, 2000
Fandrey J, Frede S, Jelkmann W: Role of hydrogen peroxide in hypoxia-induced erythropoietin production. Biochem J 303: 507–510, 1994
Chandel NS, Maltepe E, Goldwasser E, Mathieu CE, Simon MC, Schumacker PT: Mitochondrial reactive oxygen species trigger hypoxia-induced transcription. Proc Natl Acad Sci USA 95: 11715–11720, 1998
Chandel NS, McClintock DS, Feliciano CE, Wood TM, Melendez JA, Rodriguez AM, Schumacker PT: Reactive oxygen species generated at mitochondrial complex III stabilize hypoxia-inducible factor-1alpha during hypoxia: A mechanism of O2 sensing. J Biol Chem 275: 25130–25138, 2000
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Gao, N., Shen, L., Zhang, Z. et al. Arsenite induces HIF-1α and VEGF through PI3K, Akt and reactive oxygen species in DU145 human prostate carcinoma cells. Mol Cell Biochem 255, 33–45 (2004). https://doi.org/10.1023/B:MCBI.0000007259.65742.16
Issue Date:
DOI: https://doi.org/10.1023/B:MCBI.0000007259.65742.16